Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Meetings & Events

Trans-NIH Angiogenesis Workshop; May 20-21, 2013
  • Speaker Biosketches

    Portrait of James Herman, MD

    James Herman, MD
    (Johns Hopkins Medical Institutions)

    Dr.James Herman has been involved in the study of cancer epigenetics since his research fellowship in 1993. The Herman lab primarily focuses on changes in DNA methylation in cancer and was the first to demonstrate that tumor suppressor genes are silenced by promoter region methylation. Current research is aimed at utilizing these findings to improve the management of patients through the development of prognostic and predictive epigenetic biomarkers, and in studies of epigenetic therapy. They have developed new methods for the study of DNA methylation (methylation specific PCR, in situ MSP, ERMA, and more recently nanotechnology based detection methods, included MS-QFRET and MOB). These approaches are being used for the early detection of cancer. Dr. Herman is a member of TCGA (The Cancer Genome Atlas) and SU2C (stand up to cancer), to characterize genome wide epigenetic changes in cancer and determine mechanisms of epigenetic therapies, both in leukemia/myelodysplasia and in solid tumor

    « Previous  |  Next »

Workshop Organizer: NIH

NCI:Nancy Emenaker, PhD, RD
Suzanne Forry-Schaudies, PhD
NHLBI: Yunling Gao, MD, PhD
NIDDK: Teresa Jones, MD

NIH - National Institutes of Health: Turning Discovery Into Health

Back to top

Trans-NIH Angiogenesis header